Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 265

1.

A Phase 2 study of a purified, inactivated virus vaccine to prevent Japanese encephalitis.

Lyons A, Kanesa-thasan N, Kuschner RA, Eckels KH, Putnak R, Sun W, Burge R, Towle AC, Wilson P, Tauber E, Vaughn DW.

Vaccine. 2007 Apr 30;25(17):3445-53. Epub 2007 Jan 4.

PMID:
17241714
2.

Chimeric live, attenuated vaccine against Japanese encephalitis (ChimeriVax-JE): phase 2 clinical trials for safety and immunogenicity, effect of vaccine dose and schedule, and memory response to challenge with inactivated Japanese encephalitis antigen.

Monath TP, Guirakhoo F, Nichols R, Yoksan S, Schrader R, Murphy C, Blum P, Woodward S, McCarthy K, Mathis D, Johnson C, Bedford P.

J Infect Dis. 2003 Oct 15;188(8):1213-30. Epub 2003 Oct 3.

PMID:
14551893
3.

Allergic reactions to Japanese encephalitis vaccine.

Plesner AM.

Immunol Allergy Clin North Am. 2003 Nov;23(4):665-97. Review. Erratum in: Immunol Allergy Clin North Am. 2004 May;24(2):335.

PMID:
14753386
4.

Non-clinical and phase I clinical trials of a Vero cell-derived inactivated Japanese encephalitis vaccine.

Kuzuhara S, Nakamura H, Hayashida K, Obata J, Abe M, Sonoda K, Nishiyama K, Sugawara K, Takeda K, Honda T, Matsui H, Shigaki T, Kino Y, Mizokami H, Tanaka M, Mizuno K, Ueda K.

Vaccine. 2003 Nov 7;21(31):4519-26.

PMID:
14575762
5.

IMOJEV(®): a Yellow fever virus-based novel Japanese encephalitis vaccine.

Appaiahgari MB, Vrati S.

Expert Rev Vaccines. 2010 Dec;9(12):1371-84. doi: 10.1586/erv.10.139. Review.

PMID:
21105774
6.

Immunogenicity, safety and tolerability in adults of a new single-dose, live-attenuated vaccine against Japanese encephalitis: Randomised controlled phase 3 trials.

Torresi J, McCarthy K, Feroldi E, Méric C.

Vaccine. 2010 Nov 23;28(50):7993-8000. doi: 10.1016/j.vaccine.2010.09.035. Epub 2010 Oct 8.

PMID:
20934459
7.

Comparison of a single, high-dose vaccination regimen to the standard regimen for the investigational Japanese encephalitis vaccine, IC51: a randomized, observer-blind, controlled Phase 3 study.

Schuller E, Klade CS, Wölfl G, Kaltenböck A, Dewasthaly S, Tauber E.

Vaccine. 2009 Mar 26;27(15):2188-93. doi: 10.1016/j.vaccine.2008.12.062. Epub 2009 Feb 4.

PMID:
19200452
8.

Comparing the immunogenicity and safety of 3 Japanese encephalitis vaccines in Asia-Pacific area: A systematic review and meta-analysis.

Wang SY, Cheng XH, Li JX, Li XY, Zhu FC, Liu P.

Hum Vaccin Immunother. 2015;11(6):1418-25. doi: 10.1080/21645515.2015.1011996. Review.

9.

The efficacy of mouse-brain inactivated Nakayama strain Japanese encephalitis vaccine--results from 30 years experience in Taiwan.

Yang SE, Pan MJ, Tseng HF, Liau MY.

Vaccine. 2006 Mar 24;24(14):2669-73. Epub 2005 Nov 10.

PMID:
16314007
10.

A purified inactivated Japanese encephalitis virus vaccine made in Vero cells.

Srivastava AK, Putnak JR, Lee SH, Hong SP, Moon SB, Barvir DA, Zhao B, Olson RA, Kim SO, Yoo WD, Towle AC, Vaughn DW, Innis BL, Eckels KH.

Vaccine. 2001 Aug 14;19(31):4557-65.

PMID:
11483284
11.

Safety and immunogenicity of concomitant vaccination with the cell-culture based Japanese Encephalitis vaccine IC51 and the hepatitis A vaccine HAVRIX1440 in healthy subjects: A single-blind, randomized, controlled Phase 3 study.

Kaltenböck A, Dubischar-Kastner K, Eder G, Jilg W, Klade C, Kollaritsch H, Paulke-Korinek M, von Sonnenburg F, Spruth M, Tauber E, Wiedermann U, Schuller E.

Vaccine. 2009 Jul 16;27(33):4483-9. doi: 10.1016/j.vaccine.2009.05.034. Epub 2009 May 30.

PMID:
19486955
12.

Randomized, double-blind, placebo-controlled phase 3 trial of the safety and tolerability of IC51, an inactivated Japanese encephalitis vaccine.

Tauber E, Kollaritsch H, von Sonnenburg F, Lademann M, Jilma B, Firbas C, Jelinek T, Beckett C, Knobloch J, McBride WJ, Schuller E, Kaltenböck A, Sun W, Lyons A.

J Infect Dis. 2008 Aug 15;198(4):493-9. doi: 10.1086/590116. Erratum in: J Infect Dis. 2010 Apr 15;201(8):1278.

13.

Immunogenicity of an inactivated Japanese encephalitis vaccine (JE-VAX) in humans over 20 years at USAMRIID: using PRNT50 as an endpoint for immunogenicity.

Reisler RB, Danner DK, Gibbs PH.

Vaccine. 2010 Mar 11;28(12):2436-41. doi: 10.1016/j.vaccine.2009.12.080. Epub 2010 Jan 8.

PMID:
20060946
14.

Concomitant or sequential administration of live attenuated Japanese encephalitis chimeric virus vaccine and yellow fever 17D vaccine: randomized double-blind phase II evaluation of safety and immunogenicity.

Nasveld PE, Marjason J, Bennett S, Aaskov J, Elliott S, McCarthy K, Kanesa-Thasan N, Feroldi E, Reid M.

Hum Vaccin. 2010 Nov;6(11):906-14. doi: 10.4161/hv.6.11.12854. Epub 2010 Nov 1.

15.

Long-term immunogenicity of the new Vero cell-derived, inactivated Japanese encephalitis virus vaccine IC51 Six and 12 month results of a multicenter follow-up phase 3 study.

Schuller E, Jilma B, Voicu V, Golor G, Kollaritsch H, Kaltenböck A, Klade C, Tauber E.

Vaccine. 2008 Aug 12;26(34):4382-6. doi: 10.1016/j.vaccine.2008.05.081. Epub 2008 Jun 17.

PMID:
18599165
16.

A randomized study of the immunogenicity and safety of Japanese encephalitis chimeric virus vaccine (JE-CV) in comparison with SA14-14-2 vaccine in children in the Republic of Korea.

Kim DS, Houillon G, Jang GC, Cha SH, Choi SH, Lee J, Kim HM, Kim JH, Kang JH, Kim JH, Kim KH, Kim HS, Bang J, Naimi Z, Bosch-Castells V, Boaz M, Bouckenooghe A.

Hum Vaccin Immunother. 2014;10(9):2656-63. doi: 10.4161/hv.29743. Epub 2014 Nov 6.

17.

Single dose of inactivated Japanese encephalitis vaccine with poly(gamma-glutamic acid) nanoparticles provides effective protection from Japanese encephalitis virus.

Okamoto S, Yoshii H, Ishikawa T, Akagi T, Akashi M, Takahashi M, Yamanishi K, Mori Y.

Vaccine. 2008 Jan 30;26(5):589-94. doi: 10.1016/j.vaccine.2007.11.067. Epub 2007 Dec 17.

PMID:
18180081
18.
19.

Japanese encephalitis vaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.

Puthanakit T, Aurpibul L, Yoksan S, Sirisanthana T, Sirisanthana V.

Vaccine. 2007 Nov 28;25(49):8257-61. Epub 2007 Oct 11.

PMID:
17964009
20.

Immunogenicity of one dose of Vero cell culture-derived Japanese encephalitis (JE) vaccine in adults previously vaccinated with mouse brain-derived JE vaccine.

Woolpert T, Staples JE, Faix DJ, Nett RJ, Kosoy OI, Biggerstaff BJ, Johnson BW, Sracic M, Fischer M.

Vaccine. 2012 Apr 26;30(20):3090-6. doi: 10.1016/j.vaccine.2012.02.063. Epub 2012 Mar 6.

PMID:
22406277

Supplemental Content

Support Center